LifeStance Health (LFST): Wall Street Turns Clearly Bullish After Q2 Print
Sentiment has turned clearly bullish following LifeStance Health’s (NASDAQ: LFST) Q2 print, though one big outlier data source is worth flagging and largely discounting.
Post-Earnings Analyst Moves (Most Current – Aug 6–7, 2026)
- Morgan Stanley raised its price target to $16 (from $10) and reaffirmed an Overweight / Buy rating.
- BMO Capital also raised its target to $16 (from $10).
- BTIG raised its target to $16 (from $15).
- At least one additional analyst reiterated a Buy, citing the strong top-line beat, the raised full-year outlook, and the new $100 million share-repurchase authorization as evidence of improving fundamentals.
The stock rose more than 13% on the day following the print.
Company guidance itself moved higher: full-year 2026 revenue view raised to $1.685B–$1.725B from the prior $1.64B–$1.68B range. Q2 EPS came in at 6¢ versus 8¢ consensus — a miss on the bottom line even as the top line and forward guide beat expectations.
Consensus Picture (Slightly Conflicting Sources)
- One tracker shows 5 analysts with a “Strong Buy” consensus and an average target of roughly $8.50 (appears stale relative to the fresh post-earnings moves).
- A broader set shows 9 Buy ratings, 2 Holds, and zero Sells, with a target range of $9–$15 and an average near $12.
- A separate, more current source has the average target moved up toward $13, consistent with the Morgan Stanley and BMO post-earnings actions.
One Outlier to Flag and Mostly Discount
One algorithmic forecasting site shows a wildly bearish 30-day target of roughly $0.51 — an implied average decline of approximately –92% from recent trading levels. This reads as a pure statistical/algorithmic outlier that is wildly inconsistent with every actual sell-side analyst source listed above (all of whom are bullish, post-earnings, and attach real names and dated research). Treat it as noise rather than signal.
Bottom Line
The actual Wall Street analyst community — the firms with names and August 6–7 dated actions — is meaningfully more bullish after the Q2 report. Fresh price targets are clustering in the $13–$16 range on a stock that closed the print week up double digits. Revenue guidance was raised, a new $100 million buyback was authorized, and the top line continues to show solid growth.
That said, this is a forecast and sentiment summary, not investment advice. I am not a financial advisor. Price targets are analyst opinions, not guarantees. Always do your own due diligence.
WFPX Communications & Publishing / CashLeaks · For informational purposes only.
Leave a Reply